semaglutide and metformin together Efficacy safety of combined with in treating T2DM with overweight or obesity: a systematic review and meta-analysis Changes from baseline (before initiation

About the study Researchers conducted a retrospective cohort study using de-identified electronic health records from the TriNetX United States Collaborative Network between January 2020 and November 2025

Genetics, metabolic history, starting weight, duration of treatment, and lifestyle factors all play roles

This can contribute to a lower risk of heart disease, which is often a concern for individuals with obesity or metabolic disorders

Oral GLP-1 agonists havent quite caught on yet, primarily due to (1) issues with absorption, which necessitates higher dosing than injectables and may impact efficacy, and (2) fasting restrictions (must be taken on an empty stomach)

We recommend a proactive monitoring schedule: Initial Monitoring: Test your thyroid levels (TSH and Free T4) before starting tirzepatide to establish a baseline